Navigation Links
Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Date:2/7/2013

SUNNYVALE, Calif., Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three and six months ended December 31, 2012  after the NASDAQ Market closes on Thursday, February 14, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the six months ended December 31, 2012 represent a transition period, with the next fiscal year covering the period from January 1, 2013 through December 31, 2013.

Conference call and webcast details:

Date: February 14, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 409002

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when
'/>"/>

SOURCE PHARMACYCLICS/ ACCOUNTS PAYABLE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014  RedRick Technologies, ... solutions and reading room environment guidance, has helped ... musculoskeletal radiology reading room, which may also serve ... at Penn Medicine. "In line ... American College of Radiology,s Imaging 3.0 ™ ...
(Date:11/21/2014)... Depomed, Inc. (NASDAQ: DEPO ) today announced ... Annual Healthcare Conference in New York City ... scheduled for 8:00 am EST (5:00 am PST) on Tuesday December ... be accessed via the Investor Relations page of the Depomed website ... archived for 30 days on the company,s website. ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... , , ROCKVILLE, Md. , ... ) announced today that the company has decided to discontinue ... ROVI Pharmaceuticals ( Madrid : ROVI) to develop Novavax,s virus-like-particle ... .  This decision is due to the companies, inability to ...
... , SALT LAKE CITY , Feb. ... Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory systems, ... Company  received a NASDAQ Staff Deficiency Letter indicating that the ... Rule requires the Company to have at least three independent ...
Cached Medicine Technology:Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605 2
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... Karen Ignagni, President and CEO of America,s Health Insurance ... the President,s budget:"Today,s budget submission sends a signal to ... prioritizing health care. We applaud the President for ... resources to put our nation on a path towards ...
... SEO Online PR & Marketing Consultancy, is pleased to announce the ... successful Industry Directory, offering free listings to relevant specialist industries. ... ... B2B, SEO Online PR & Marketing Consultancy , is pleased ...
... N.C., Feb. 26 Arbor Pharmaceuticals, a specialty,pharmaceutical ... the company has launched XYLAREX - a first-in-class ... media (middle ear,infections). XYLAREX is a novel ... the number of ear infections children experience. ...
... Feb. 26 A lawsuit was filed today by ... who contracted salmonella poisoning,after eating at a Blueberry Hill ... child was hospitalized for three days as a result ... Cook County Department of Health,after the Communicable Disease Unit ...
... groups nationwide to receive National Autism Conference DVD ... Association (NAA) today announced its receipt of a ... (CWF) to disseminate DVD sets of complete presentations ... organizations throughout the United States, U.S. territories, and ...
... to continuing multi-pronged effort to raise awarenessWASHINGTON, Feb. 26 ... for a Drug-Free America offers some promising news regarding ... According to the 20th annual Partnership Attitude Tracking Survey ... about drugs and alcohol, an increased number of teens ...
Cached Medicine News:Health News:AHIP Statement on the President's Budget 2Health News:Simply Marcomms Launch New Specialist Online Industry Directories 2Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2Health News:National Autism Association Announces American Legion Child Welfare Grant for Autism Outreach 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 3
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... primary known naturally-occurring stimulant of red blood ... human EPO is 18.2 kDa. Due to ... an estimated molecular mass of ~30.5 kDa. ... unique structure, the EPO receptor bears some ...
... Alpha Fetoprotein (AFP) is a 68 kDa protein, ... the fetal liver and yolk sac [1]. ... weeks gestation, and production rates reach 19-26 g/min ... and estimates of total fetal AFP continue to ...
Medicine Products: